Publications by authors named "J Bargay"
This study examines the impact of cytogenetic abnormalities and their co-segregation on the prognosis of newly diagnosed multiple myeloma patients. The analysis included 1304 patients from four different GEM-PETHEMA clinical trials. Genetic alterations, such as t(4;14), t(14;16), del(17p), +1q, and del(1p), were investigated using FISH on CD38 purified plasma cells.
View Article and Find Full Text PDFArticle Synopsis
- The study examined the impact of immunoparesis (IP) recovery on the prognosis of 113 newly diagnosed transplant-ineligible multiple myeloma (MM) patients who received a fixed treatment regimen and achieved complete or very good partial responses.
- Results showed that patients who initially had IP and then experienced recovery during or after treatment had significantly longer progression-free survival (PFS) and overall survival (OS) compared to those who did not recover.
- Additionally, among MRD negative patients, those with IP recovery also demonstrated improved PFS and OS, highlighting that IP recovery can enhance prognostic evaluations in combination with MRD status in this patient population.
Article Synopsis
- - In a study of 138 multiple myeloma (MM) patients, researchers explored the benefits of monitoring peripheral residual disease (PRD) in blood instead of relying solely on more invasive bone marrow (BM) assessments.
- - Positive PRD results from next-generation flow (NGF) indicated a significantly higher risk of disease progression/death, and those with undetectable PRD had excellent survival rates.
- - The findings suggest that PRD monitoring is a valuable and less cumbersome method for identifying patients at risk of relapse during maintenance treatment in transplant-eligible MM patients.
Quantitative immunoprecipitation mass spectrometry (QIP-MS) allows the identification of the M-protein in patients with multiple myeloma (MM) otherwise in complete response, and could be considered suitable for measurable residual disease (MRD) evaluation in peripheral blood. In the context of the GEM2012MENOS65 and GEM2014MAIN trials, we compared the performance of QIP-MS in serum with next-generation flow (NGF) cytometry in bone marrow to assess MRD in paired samples obtained postinduction, transplant, consolidation and after 24 cycles of maintenance. At each time point, both NGF and QIP-MS were able to segregate 2 groups of patients with significantly different progression-free survival; when the evolution of the results obtained with either method was considered, maintaining or converting to MRD negativity was associated with longer survival, significantly better when compared with sustaining or converting to MRD positivity.
View Article and Find Full Text PDFArticle Synopsis
- Lenalidomide (LEN) can help 60-70% of patients with del(5q) myelodysplastic neoplasm achieve independence from red blood cell transfusions (RBC-TI), but there's a concern about its toxicity and cost.
- The HARMONY Alliance study followed 118 low-intermediate risk MDS patients who discontinued LEN, finding that 50 lost RBC-TI after a median of 49 months.
- Factors like having a low transfusion burden before treatment, completing at least 12 LEN cycles, being younger, and having higher hemoglobin levels at withdrawal were linked to longer RBC-TI duration after discontinuing LEN.